TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18691791

Group type: EXPERIMENTAL
Intervention: Point-of-care testing
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Central laboratory markers only (laboratory arm)
Number of subjects: 2000
Study: 18056489

Group type: EXPERIMENTAL
Intervention: Simple decompression
Number of subjects: 361

Group type: COMPARATOR
Intervention: Anterior transposition of the ulnar nerve
Number of subjects: 361
Study: 15230343

Group type: EXPERIMENTAL
Intervention: 100 mg disodium clodronate with 1% lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clody (same formulation without local anaesthetic)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clasteon (marketed formulation containing 1% benzyl alcohol)
Number of subjects: 30
Study: 12131187

Group type: EXPERIMENTAL
Intervention: HIV-specific CD8 T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMV-specific CD8 T cells
Number of subjects: 0
Study: 9823912

Group type: EXPERIMENTAL
Intervention: [18F]fluorodeoxyglucose (FDG) PET scan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 50
Study: 7911813

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg twice weekly)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Quinagolide (75 micrograms once daily)
Number of subjects: 12
Study: 2593891

Group type: EXPERIMENTAL
Intervention: Dietitian advice (n = 31)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Diet fact sheet (n = 28)
Number of subjects: 59
Study: 183605

Group type: EXPERIMENTAL
Intervention: BCG immunoprophylaxis
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30839438

Group type: EXPERIMENTAL
Intervention: Vessel loop drainage
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard incision and drainage (I&D)
Number of subjects: 81
Study: 30986791

Group type: EXPERIMENTAL
Intervention: RotaTeq vaccine
Number of subjects: 19133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19133
Study: 28123149

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 144
Study: 26688732

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 48.75 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI (pooled data)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo 32.5 mg
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo 48.75 mg
Number of subjects: 286
Study: 23576486

Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil
Number of subjects: 442
Study: 21041278

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy (40 mg/day) combined with methotrexate (MTX; 0.2 mg/kg/week) and prednisone (10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methotrexate (MTX; 0.2 mg/kg/week) plus prednisone (10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 30
Study: 19124513

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 minutes per week of moderate‐intensity)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (maintaining current physical activity level)
Number of subjects: 75
Study: 17219217

Group type: EXPERIMENTAL
Intervention: Alprazolam XR (1 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alprazolam IR (1 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15145877

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTCA (balloon angioplasty)
Number of subjects: 0
Study: 11059965

Group type: EXPERIMENTAL
Intervention: Salmeterol added to low-dose inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8872688

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg orally
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 1623899

Group type: EXPERIMENTAL
Intervention: Metamizole 3 x 1 g for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide 20 mg IV
Number of subjects: 12
Study: 6367875

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Self-exposure homework
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spontaneous panics
Number of subjects: 45
Study: 30690511

Group type: EXPERIMENTAL
Intervention: EPS trajectory
Number of subjects: 9

Group type: COMPARATOR
Intervention: S1AS trajectory
Number of subjects: 9
Study: 29299776

Group type: EXPERIMENTAL
Intervention: Monetary reward for fast and accurate task performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: No monetary reward (control group)
Number of subjects: 0
Study: 26650133

Group type: EXPERIMENTAL
Intervention: Milking of the cord 4 times
Number of subjects: 58

Group type: COMPARATOR
Intervention: Delayed cord clamping
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Milking of the cord 4 times (girls)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Milking of the cord 4 times (boys)
Number of subjects: 58
Study: 25651293

Group type: EXPERIMENTAL
Intervention: Horizontal incision
Number of subjects: 63

Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 63
Study: 24308310

Group type: EXPERIMENTAL
Intervention: Baduanjin training (1 hour per day, 5 days per week for 12 weeks)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual exercise control group
Number of subjects: 222
Study: 20409311

Group type: EXPERIMENTAL
Intervention: Aerobic training alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Resistance training alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance training
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attention-control (progressive stretching)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All exercise training groups
Number of subjects: 160
Study: 17984104

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Rigorous BP control
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard BP control
Number of subjects: 46
Study: 15710957

Group type: EXPERIMENTAL
Intervention: Combination therapy with pegylated interferon-alpha2b (1.5 microg/kg/week for 32 weeks) plus lamivudine (100 mg daily for 52 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg daily for 52 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 100
Study: 12804927

Group type: EXPERIMENTAL
Intervention: Thrombolysis alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Thrombolysis plus abciximab
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: High CRP group (CRP >12 mg/l)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Low CRP group (CRP ≤12 mg/l)
Number of subjects: 250
Study: 11029125

Group type: EXPERIMENTAL
Intervention: Tramadol drops (2.5 mg kg(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paracetamol (acetaminophen) suppositories (15 mg kg(‐1))
Number of subjects: 50
Study: 8711649

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators or steroids
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Diagnosis of asthma or chronic bronchitis
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Respiratory symptoms
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Potential improvement on treatment
Number of subjects: 783
Study: 1355345

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg/day for 15 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Astemizole 10 mg/day for 15 days
Number of subjects: 34
Study: 6432869

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NG) for 48 hours
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 31731467

Group type: EXPERIMENTAL
Intervention: Coffee ingestion (0.09 g·kg‐1 coffee providing 3 mg·kg‐1 of caffeine)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 38
Study: 29949041

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/linagliptin 5 mg
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/linagliptin 5 mg
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin or empagliflozin
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1363
Study: 27655505

Group type: EXPERIMENTAL
Intervention: Mechanical fragmentation combined with rt‐PA artery thrombolysis
Number of subjects: 132

Group type: COMPARATOR
Intervention: rt‐PA artery thrombolysis
Number of subjects: 132
Study: 24830742

Group type: EXPERIMENTAL
Intervention: Bilateral external ventricular drains (EVD)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Single external ventricular drain (EVD)
Number of subjects: 47
Study: 22369221

Group type: EXPERIMENTAL
Intervention: PTSD severity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Startle and anger/irritability symptoms of PTSD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nightmares, emotional numbing, and hypervigilance symptoms of PTSD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Anger/irritability symptom of PTSD
Number of subjects: 29
Study: 20214894

Group type: EXPERIMENTAL
Intervention: Metformin therapy for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no metformin therapy)
Number of subjects: 20
Study: 18758125

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 2.5 mg/dL
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-rosuvastatin therapy
Number of subjects: 38
Study: 15641102

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 20
Study: 12621384

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally twice a day for 2 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Grapefruit juice 200 mL 3 times a day for 2 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10321418

Group type: COMPARATOR
Intervention: 8 mg conventional ondansetron tablet (OT) taken twice daily
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: 8 mg orally disintegrating ondansetron tablet (ODT) taken twice daily
Number of subjects: 427
Study: 8317343

Group type: EXPERIMENTAL
Intervention: Microdialysis method to collect dialysate samples from inflamed tissue
Number of subjects: 0
Study: 2883698

Group type: EXPERIMENTAL
Intervention: midazolam 15 mg orally followed by intravenous saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: oral placebo followed by intravenous diazepam 10 mg (Diazemuls)
Number of subjects: 40
Study: 27768384

Group type: EXPERIMENTAL
Intervention: Family group cognitive behavioral intervention (FGCB)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Written information (WI) control
Number of subjects: 242
Study: 26855120

Group type: EXPERIMENTAL
Intervention: Omega-3 highly unsaturated fatty acids (n-3 HUFAs) supplementation in the form of all natural fruit juice beverages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (all natural fruit juice beverages)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 HUFAs
Number of subjects: 0
Study: 25186034

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo advanced to tofacitinib 5 mg twice daily
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo advanced to tofacitinib 10 mg twice daily
Number of subjects: 399
Study: 23850450

Group type: EXPERIMENTAL
Intervention: AC-T (doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 201

Group type: COMPARATOR
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: AC-T without primary G-CSF prophylaxis
Number of subjects: 201

Group type: COMPARATOR
Intervention: TAC with primary G-CSF prophylaxis
Number of subjects: 201
Study: 21670542

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg b.i.d.
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg b.i.d.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0-3.0; 2.0-2.6 if age ≥ 70 years)
Number of subjects: 222
Study: 19567532

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA daily for 2 years (women)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 75 mg DHEA daily for 2 years (men)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5 mg testosterone (patch) daily for 2 years (men)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo daily for 2 years (women and men)
Number of subjects: 122
Study: 16123739

Group type: EXPERIMENTAL
Intervention: DMT (low dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DMT (high dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: S-ketamine (low dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: S-ketamine (high dose)
Number of subjects: 15
Study: 15127564

Group type: EXPERIMENTAL
Intervention: Radical neck dissection (RND)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Functional neck dissection (FND)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (RND and FND)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Negative cervical lymph nodes
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Positive cervical lymph nodes
Number of subjects: 76
Study: 11313302

Group type: EXPERIMENTAL
Intervention: CDP571 (10 or 20 mg/kg)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 9807987

Group type: EXPERIMENTAL
Intervention: Irinotecan plus supportive care
Number of subjects: 279

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 279
Study: 7977475

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 125 mg twice a day for 2 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cefuroxime axetil, 125 mg twice a day for 10 days
Number of subjects: 50
Study: 2647995

Group type: EXPERIMENTAL
Intervention: Regimen A (pentobarbital, prochlorperazine, and dexamethasone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regimen B (dexamethasone, prochlorperazine, and placebo)
Number of subjects: 12
Study: 30673852

Group type: EXPERIMENTAL
Intervention: Initial lesion diameter
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Cavitated lesions
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Focal lesions without cavitation
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Disappeared lesions
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Initial NIHSS score
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Diameter of initial lesion
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Number of slices showing acute lesion on DWI
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Progression of white matter lesion
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Number of acute lesions involving gray matter
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Lesion location
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Diameter of acute lesion, initial number of old lacunes, anterior lesion location
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Initial lesion diameter, posterior lesion location
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Reduction of acute lacunar lesion diameter
Number of subjects: 509
Study: 28346581

Group type: EXPERIMENTAL
Intervention: Home-based hypnotherapy using a CD (CD group)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Individual hypnotherapy performed by qualified therapists (iHT group)
Number of subjects: 260
Study: 26159609

Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM) at 33°C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted Temperature Management (TTM) at 36°C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to Return of Spontaneous Circulation (ROSC)
Number of subjects: 0
Study: 23341981

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation (BMMCT) combined with standard medical therapy (SMT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups (BMMCT and SMT)
Number of subjects: 58
Study: 20462466

Group type: EXPERIMENTAL
Intervention: Sertraline plus Self-Administered Cognitive Behavior Therapy (SCBT)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo plus SCBT
Number of subjects: 251

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 18434890

Group type: EXPERIMENTAL
Intervention: Prestorage leukoreduced blood transfusions
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard allogeneic blood transfusions
Number of subjects: 268
Study: 16505129

Group type: EXPERIMENTAL
Intervention: Collaborative care for depression
Number of subjects: 901

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Intervention patients (Collaborative care)
Number of subjects: 901
Study: 12931208

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 30
Study: 11128731

Group type: EXPERIMENTAL
Intervention: Individualized rehabilitation programme at home after stroke
Number of subjects: 41
Study: 9372546

Group type: EXPERIMENTAL
Intervention: Porfiromycin (50 mg/M2, 45 mg/M2, 40 mg/M2) with radiation therapy (RT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mitomycin C with radiation therapy (RT)
Number of subjects: 21
Study: 8403155

Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine 1 mg.kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5% heavy lidocaine 1.2 to 1.4 ml intrathecally
Number of subjects: 50
Study: 3512080

Group type: EXPERIMENTAL
Intervention: mazindol (1 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 30261868

Group type: EXPERIMENTAL
Intervention: Four-day interactive training course on action-oriented home visits to pregnant women and infants.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 78
Study: 27181196

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 307

Group type: COMPARATOR
Intervention: Conservative treatment for 3 months
Number of subjects: 307
Study: 24987061

Group type: EXPERIMENTAL
Intervention: Cetuximab (in CAPOX-C arm)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Homozygous for 131H and/or 158V (Control group)
Number of subjects: 164
Study: 22950591

Group type: EXPERIMENTAL
Intervention: Functioning Improvement Tool (FIT) home visit program (60 minutes)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Home visit using conversation alone (30 minutes)
Number of subjects: 28
Study: 20398300

Group type: EXPERIMENTAL
Intervention: 7 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: 10 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Moxifloxacin resistant strains
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Moxifloxacin sensitive strains
Number of subjects: 150
Study: 18831984

Group type: EXPERIMENTAL
Intervention: Target contrast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distractor contrast
Number of subjects: 0
Study: 16143734

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg/d
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 11953922

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Free diet intake
Number of subjects: 69
Study: 10511939

Group type: EXPERIMENTAL
Intervention: 1.1 mm TurboSonics
Number of subjects: 119

Group type: COMPARATOR
Intervention: 0.9 mm MicroTip
Number of subjects: 119
Study: 7579027

Group type: EXPERIMENTAL
Intervention: Single oral doses of reboxetine (2, 3, 4, and 5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reboxetine (4 mg therapeutic tablet formulation)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reboxetine (various doses)
Number of subjects: 15
Study: 1834808

Group type: EXPERIMENTAL
Intervention: Toremifene (10, 20, 40, 60, 200, or 400 mg/d orally) for at least 8 weeks
Number of subjects: 107
Study: 6772047

Group type: EXPERIMENTAL
Intervention: Dihydrazinophthalazine (Nepresol) 45 +/- 12 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 32
Study: 30337189

Group type: EXPERIMENTAL
Intervention: Weaning at 1600 g
Number of subjects: 366

Group type: COMPARATOR
Intervention: Weaning at 1800 g
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 366